Phase Ib/IIa Study of Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Ibcasertib (Primary) ; Tucidinostat (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Chipscreen Biosciences
- 07 Mar 2022 Status changed from recruiting to completed.
- 09 Aug 2021 Planned End Date changed from 1 Sep 2021 to 1 Dec 2021.
- 09 Aug 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Dec 2021.